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Human p53 interacts with the 
elongating RNAPII complex 
and is required for the release 
of actinomycin D induced 
transcription blockage
Barbara N. Borsos1, Ildikó Huliák1, Hajnalka Majoros1, Zsuzsanna Ujfaludi1, Ákos Gyenis2, 
Peter Pukler1, Imre M. Boros1,3 & Tibor Pankotai1
The p53 tumour suppressor regulates the transcription initiation of selected genes by binding to specific 
DNA sequences at their promoters. Here we report a novel role of p53 in transcription elongation in 
human cells. Our data demonstrate that upon transcription elongation blockage, p53 is associated 
with genes that have not been reported as its direct targets. p53 could be co-immunoprecipitated with 
active forms of DNA-directed RNA polymerase II subunit 1 (RPB1), highlighting its association with 
the elongating RNA polymerase II. During a normal transcription cycle, p53 and RPB1 are localised at 
distinct regions of selected non-canonical p53 target genes and this pattern of localisation was changed 
upon blockage of transcription elongation. Additionally, transcription elongation blockage induced 
the proteasomal degradation of RPB1. Our results reveal a novel role of p53 in human cells during 
transcription elongation blockage that may facilitate the removal of RNA polymerase II from DNA.
The transcription of protein-coding genes in eukaryotic cells is catalysed by a 12-subunit (RPB 1–12) enzyme, 
RNA polymerase II (RNAPII). In the process of initiation, the general transcription factors (TFIIB, D, E, F and H) 
are recruited to promoters and the unphosphorylated RNAPII associates with them, forming the pre-initiation 
complex (PIC)1. At this stage, the C-terminal domain (CTD) of RPB1 becomes phosphorylated at its Ser-5 resi-
dues (S5P) by Cdk-7, while during a later phase of transcription elongation, RPB1 CTD will be phosphorylated 
at its Ser-2 residues (S2P) by Cdk-92. These modifications are tightly associated with RNA capping, splicing and 
polyadenylation3,4.
Additionally, DNA damage-induced transcription blockage also affects the phosphorylation state of RPB1. 
This could activate the binding of specific factors to the RNAPII complex with various outcomes5. If irrevers-
ible transcription blockage occurs, the RNAPII is polyubiquitylated and degraded by the 26S proteasome6,7. 
The ubiquitin-proteasome system (UPS)-mediated elimination of RNAPII from the site of DNA damage allows 
the repair of DNA lesions8–11. It has been shown that proteins in different DNA damage repair processes, such 
as CSA (Cockayne syndrome A), BRCA1 (Breast cancer 1), BARD1 complex (BRCA1-associated RING) and 
NEDD4 (neural precursor cell expressed, developmentally down-regulated 4), are involved in the ubiquitylation 
of RNAPII12–17. Recently it has also been reported that the 26S proteasome can be directly recruited to the dam-
aged chromatin region for the efficient degradation of the ubiquitylated RNAPII18. In accordance with this, it has 
been demonstrated that the S2P forms of RPB1 are better substrates for proteasomal degradation, which indicates 
that the elongating form of RNAPII can be targeted for degradation19. Finally, the proteasome itself is also present 
at transcriptionally active gene regions where RNAPII density is high, which underlines the notion that the pro-
teasome might have a role at chromatin sites, where transcription arrest occurs20,21.
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p53 is a stress-activated, sequence-specific transcription factor, which binds to consensus sequences at the 
promoter and distal regions of its target genes (e.g. Bax, Bad, and P21). p53 also acts as a tumor suppressor that 
can induce apoptosis upon serious DNA damage by releasing pro-apoptotic factors from the mitochondria or 
activating the transcription of pro-apoptotic factors, and it can also induce cell cycle arrest22,23.
Upon DNA damage, transcription blockage occurs, p53 is phosphorylated by ATR (ataxia telangiectasia and 
Rad3 related) kinase, and DNA repair proteins are activated to remove the lesions5. Additionally, upon tran-
scription elongation blockage, ATM-mediated Ser-15 phosphorylation and p300-mediated Lys-382 acetylation 
stabilises p535,24,25. These two post-translational modifications of p53 have an indispensable role in p53-mediated 
signalisation during cell cycle arrest and apoptosis induction26–28.
In addition to its role as a sequence-specific DNA-binding factor in transcription initiation, p53 could 
facilitate transcription by interacting with proteins involved in transcription elongation (e.g. TFIIH, ELL and 
hPAF1C)29–31. In accordance with this, the human p53 protein has been reported to associate with coding regions 
of RNAPII-transcribed genes in a heterologous system32. It was previously shown that Dmp53 (Drosophila mela-
nogaster p53) was localised at transcriptionally active regions on the Drosophila polytene chromosomes and that 
the phosphorylation state of RPB1 CTD influenced its localisation33.
Here we describe the results of experiments investigating whether the p53 protein was able to bind to gene 
regions that were not its direct targets, due to the presence of specific binding site(s) at their regulatory regions. 
We examined whether the binding of p53 to non-canonical target gene regions changed upon transcription elon-
gation blockage induced with a high dose of actinomycin D (ActD). Furthermore, we asked whether an inter-
action between p53 and phosphorylated forms of RPB1 (S2P and S5P) could be detected in human cells and 
how it was altered upon ActD-induced inhibition of transcription elongation. We found that p53 binds to gene 
regions that are non-canonical targets and the binding takes place presumably through the interaction between 
p53 and RPB1. During transcription elongation blockage, RPB1 occupancy is reduced on the chromatin, while 
p53 binding can be detected at most of the examined promoters and distal gene bodies, particularly shortly after 
the induction of the transcription blockage. Upon transcription stress, the cellular p53 level is increased, while the 
RPB1 protein level is decreased as a result of proteasomal degradation of RPB1.
These observations highlight a mechanism by which transcription blockage that occurs due to different types 
of DNA damage could be resolved. The mechanism we propose here helps to understand how the RNAPII is 
degraded on a damaged transcribed unit in order to allow access for repair proteins. We assume that by this 
mechanism, cells can avoid producing truncated or mutated transcripts from essential genes that would endanger 
cell viability.
Results
Human p53 interacts and co-localises with RNAPII on chromatin. p53 has been reported to interact 
with proteins involved in transcription elongation, such as TFIIH (Transcription Factor II H)30, ELL (Elongation 
factor RNA polymerase II)31 and hPAF1C (RNA polymerase-associated factor 1 complex)34, which suggests that 
p53 may have a role during transcription elongation. Interaction between human p53 and RPB1 has been shown 
in yeast32, however, the interaction between the two proteins in human cells in relation to transcription elongation 
has not been investigated yet. In order to study whether interaction between human p53 and RPB1 is detectable 
in U2OS cells, we performed co-immunoprecipitation (co-IP) experiments using specific antibodies that recog-
nise Ser2-phosphorylated RPB1 (S2P RPB1) or Ser5-phosphorylated RPB1 (S5P RPB1) forms (Fig. 1A,B). We 
performed the co-IP experiments both under normal conditions and after 6 and 24 h of transcription blockage 
induced by actinomycin D (ActD). We found that p53 was co-immunoprecipitated with S2P and S5P forms of 
RPB1 (lane 1 of Fig. 1A,B, upper panel, respectively). To prove that RPB1 interacts with S15-phosphorylated p53 
(S15P p53), which is the active form of p53, we performed co-IP experiments in control and ActD-treated cells. We 
found that the S15P p53 interacts with S2P and S5P RPB1 (lane 1 of Fig. 1A,B, middle panel, respectively). These 
results indicate that p53 interacts both with the initiating (S5P) and elongating (S2P) froms of RPB1 under normal 
conditions. To reveal whether the interaction between the two proteins was mediated by DNA, we used MNase 
before immunoprecipitation in order to eliminate DNA. We found that under normal conditions, the removal of 
DNA did not change the interaction between p53 and the elongating S2P RPB1 (Supplementary Figure 1A, lane 4).
To examine whether p53 also interacts with S2P and S5P forms of RPB1 during transcription blockage 
induced by a high concentration of ActD, we performed further co-immunoprecipitation experiments on samples 
obtained 6 and 24 h after ActD treatment. p53 could be co-immunoprecipitated with the phosphorylated forms 
of RPB1 at both time points after ActD treatment (lane 2–3 of Fig. 1A,B, upper panel, respectively). Similarly, 
we found that the S15-phosphorylated p53 also interacted with S2P and S5P RPB1 (lane 2–3 of Fig. 1A,B, mid-
dle panel, respectively). Additionally, the interaction of S2P RPB1 and p53 in MNase-treated samples could be 
detected both after 6 and 24 h of ActD treatment (Supplementary Figure 1A, lane 5–6).
To verify the above results on p53 and RNAPII interaction, we performed reciprocal co-IP experiments by 
immunoprecipitating with a p53-specific antibody and detecting specific RPB1 forms by Western blot analysis in 
the precipitated material (Fig. 1C). The results strengthened our previous experimental data that the two proteins 
interact with each other.
Taken together, the results of the co-immunoprecipitation experiments demonstrated that, both under normal 
conditions and upon transcription elongation blockage, p53 and S15P p53 interacted with the S2P form of RPB1 
(Fig. 1A–C). This could imply that p53 has a role in transcription elongation during transcription-coupled stress 
conditions in human cells.
To further support these results, we performed immunostainings on U2OS cells to detect the localisation of 
p53 and RPB1 protein forms upon treatment with a low (5 nM) or high (200 nM) concentration of ActD. In order 
to detect only the chromatin-bound proteins, we eliminated the soluble nuclear proteins before performing the 
immunostaining experiments. Upon ActD treatment, we detected higher levels of chromatin-bound p53 and 
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lower levels of RPB1 compared to the untreated controls (Fig. 2A). Our results show that p53 co-localises with the 
S2P and S5P forms of RPB1 when treated with a high concentration of ActD (Fig. 2B,C), which is in accordance 
with the co-IP results shown on Fig. 1.
Interestingly, 24 h after treatment with a high concentration of ActD, S2P and S5P RPB1 co-localise with p53 
at discrete nuclear foci, suggesting that strong RPB1-p53 interactions might take place at locations where DNA 
damage-induced transcription blockages occur (Fig. 2B,C).
ActD treatment results in DNA double-strand breaks leading to transcriptional silencing. It 
has been reported recently that ActD treatment results in DNA double-strand breaks35. In addition, in response to 
DNA damage, DNA-PK- (DNA-dependent protein kinase) and ATM-(Ataxia telangiectasia mutated) mediated 
local inhibition of transcription occurs at the site of the damage, leading to the ubiquitin-mediated degradation 
of RNAPII7,9,10. In order to demonstrate that, in our experimental setup, the ActD-induced transcription blockage 
resulted in DNA double-strand breaks (DSBs), we examined the distribution of γ H2AX and p53 by immunos-
taining, 6 and 24 h after ActD treatment (Fig. 3). While in control cells, low levels of γ H2AX and p53 could be 
observed, both γ H2AX and p53 foci numbers increased 6 and 24 h after ActD treatment (Fig. 3A), highlighting 
the locations of DSBs. Additionally, after 6 and 24 h ActD treatment, γ H2AX and p53 co-localise in discrete 
nuclear foci, marking the sites where active DNA damage repair takes place (Fig. 3A, middle and lower panel).
To reveal whether the ActD-induced DNA damage leads to transcriptional silencing, we performed immu-
nostainings and tested the co-localisation frequency between γ H2AX and the phosphorylated forms of RPB1 
following 6 and 24 h of ActD treatment. We found that neither γ H2AX and S2P RPB1 nor γ H2AX and S5P RPB1 
co-localise with each other (Fig. 3B,C), strengthening the hypothesis that transcription is inhibited where DNA 
repair takes place.
We concluded that the DNA damage response may result in complete transcriptional silencing at the DNA 
break sites. Since ATM and DNA-PK could phosphorylate the serine-15 residue of p53 in response to DNA dam-
age, we believe that RNAPII degradation is mediated by p5336–39. This mechanism is likely to be activated by the 
stalling of RNAPII and further promoted by the DNA damage-induced PI3K kinases.
Figure 1. Human p53 interacts with RPB1 both under normal circumstances and upon ActD treatment. 
(A,B) The transcriptionally active forms of RPB1 (S2P and S5P) were immunoprecipitated and the RPB1-p53 
interaction was validated by detection of p53 and S15P p53 with immunoblot using specific antibodies. (C) 
Asterisks show the unspecific signal of the IgG heavy chain. The reversal immunoprecipitation was performed 
by a p53-specific antibody. The p53-S2P RPB1 and p53-S5P RPB1 interactions were detected by specific 
antibodies against S2P and S5P RPB1 while IgG controls were used as the negative controls. (D,E) Western 
blots were performed on the input protein samples to prove the equal protein quantity for each sample used for 
the S2P S5P RPB1 (D) and p53 (E) immunoprecipitations. GAPDH was used to show the equal loading of the 
samples.
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Figure 2. p53 and RPB1 co-localise to discrete nuclear foci in U2OS cells upon ActD-induced transcription 
elongation blockage. (A–C) Co-immunostaining with p53 (green) and RPB1 (red), S2P RPB1 (red) or S5P 
RPB1 (red), respectively. Only chromatin-bound proteins are detected, because nuclear soluble proteins were 
eliminated during the immunostaining process (see Methods). Immunostainings were performed both under 
normal conditions and after 6 and 24 h treatments of 5 and 200 nM doses of ActD. Staining with DAPI (blue) 
was used to visualise nuclei.
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Figure 3. p53 and yH2AX co-localise at discrete nuclear foci upon transcription elongation blockage. 
(A) Co-immunostaining with yH2AX (red) and p53 (green). (B,C) Co-immunostaining with yH2AX (green) 
and S2P RPB1 (red) or S5P RPB1 (red), respectively. Only chromatin-bound proteins were detected, because 
nuclear soluble proteins were eliminated during the immunostaining process (see Materials and methods). 
Immunostainings were performed both under normal conditions and after 6 and 24 h treatments of 200 nM 
ActD. Staining with DAPI (blue) was used to visualise nuclei.
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p53 protein is stabilised, while RPB1 is degraded upon ActD treatment. To further investigate 
the changes in the levels of p53 and RPB1 during transcription elongation blockage, we treated U2OS cells for 6 
or 24 h with low (5 nM) or high (200 nM) concentrations of ActD then we examined p53 and RPB1 protein levels 
in whole cell extracts. The total p53 level increased shortly after treatments of both low and high concentrations 
of ActD (Supplementary Figure 2). Conversely, we detected Ser15-phosphorylated p53 (S15P p53) only upon 
200 nM ActD treatment, which supports the hypothesis that this post-translationally modified form of p53 is pres-
ent only following transcription elongation blockage or DNA double-strand breaks5 (Supplementary Figure 2). 
On the other hand, RPB1, as well as S5- and S2-phosphorylated RPB1, levels were reduced particularly after 24 h 
of high concentration ActD treatment (Fig. 4, left panel). These results indicate that p53 is stabilised, while RPB1 
may be degraded upon transcription elongation blockage.
It has already been demonstrated that transcription blockage can lead to ubiquitin-mediated proteasomal 
degradation of RNAPII7,21. To reveal whether the reduction in the level of RPB1 protein was a consequence of 
its proteasomal degradation, we treated the cells with MG132 proteasome inhibitor (20 μ M). We found that the 
levels of both RPB1 and its transcriptionally active forms (S5P and S2P) remain mostly unchanged upon ActD 
treatment (Fig. 4, right panel; Supplementary Figure 2). These results support the hypothesis that during exposure 
to stress, RPB1 is degraded by the 26S proteasome.
p53 binds to gene regions that are not its direct targets and its binding affinity is strongly 
affected by transcription elongation blockage. Since our data support the idea that p53 interacts with 
the elongating RNAPII complex, we re-analysed published ChIP-seq data that revealed the localisation of p53 
(srr847010, srr847017), S2P RPB1 (srr987275), S5P RPB1 (srr987273) and RPB1 (srr987271) in U2OS cells, in 
order to validate whether p53 binds to transcribing units (Fig. 5A)40,41. We investigated p53 occupancy profiles on 
every gene annotated in RefSeq (https://www.ncbi.nlm.nih.gov/refseq) by calculating p53 tag densities ±1.5 kb 
distances around the annotated loci. By using a k-means clustering method on the occupancies of p53 and RPB1, 
we could sort the genes into three distinct clusters. Cluster 1 showed high p53 and RPB1 occupancies at the tran-
scription start site. Cluster 2 genes showed elevated p53 and RPB1 bindings along the transcribed units. In Cluster 
3 we could detect low RPB1 binding at the TSS (Transcription start site), while p53 could not be detected on those 
genes (Fig. 5A). These data suggest a correlation between p53 occupancy and gene expression level: p53 localises 
on the genes that show higher expression rate.
Since ChIP-seq data indicated that p53 was localised at specific genes and our data also revealed that p53 was 
associated with the elongating RNAPII, we decided to perform ChIP in order to validate the binding of p53 at spe-
cific gene regions (promoter, gene body and 3′UTR) of selected groups of genes which included ActB (Cluster 1), 
Cdk12 (Cluster 1), Brat1 (Cluster 1) and Sdcbp (Cluster 2). As a positive control, we examined the regulatory 
region of a well-known p53 regulated gene, P21, while as a negative control we included an intergenic region in 
our analysis.
We found that under normal conditions, p53 associated with specific regions of genes that are not its direct 
targets, as they do not contain canonical binding sites of p53. Under normal conditions, a low level of p53 occu-
pancy could be detected at most of the examined gene regions (Fig. 5C–F, white columns). Only ActB seems to 
be an exception, since on this gene, a high level of p53 occupancy could be observed at the promoter and distal 
gene body (indicated as ‘Gene body 2’; Fig. 5B, white columns). RPB1 associated strongly at promoter regions and 
distal gene bodies of the examined genes, but showed weaker binding at the proximal gene bodies (indicated as 
‘Gene body 1’) and at 3’ end regions of the genes (Fig. 5B–F, white columns).
To investigate whether p53 occupancy is altered by transcription elongation blockage, we measured the dis-
tribution of p53 and RPB1 at the examined gene regions using a similar experiment, but after treating cells with 
a high concentration (200 nM) of ActD for 6 and 24 h (Fig. 5B–G, grey and black columns, respectively). RPB1 
Figure 4. ActD treatment destabilises RPB1 through proteasome-mediated degradation. Western blot 
detection of RPB1, S5P RPB1 and S2P RPB1 proteins in U2OS cells both under normal conditions and when 
treated with 5 and 200 nM ActD. Each experiment was performed in the absence (left panel) or in the presence 
of 20 μ M MG132 proteasome inhibitor (right panel). Coomassie Brilliant Blue staining was used to show the 
equal loading of the samples.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:40960 | DOI: 10.1038/srep40960
occupancy was reduced 6 h after ActD treatment, and then it increased 24 h after transcription blockage induc-
tion, except at the promoter regions of ActB, Brat1 and P21 (Fig. 5B,D and F, respectively). Conversely, increased 
p53 binding was detected after ActD treatment, mainly at the promoters and distal gene bodies of the examined 
genes (Cdk12, Brat1, Sdcbp and P21), and this increase was time-dependent (Fig. 5C–F, respectively). In the case 
of the ActB gene (Fig. 5B), p53 occupancy showed a similar change over time as did RPB1: the binding level was 
reduced 6 h after ActD treatment (Fig. 5B, grey columns), then it was restored 24 h after transcription blockage 
induction (Fig. 5B, black columns).
These results show p53 accumulation at transcriptionally active chromatin regions upon transcription elonga-
tion blockage. Based on our data, we propose that p53 protein co-traverses with the elongating RNAPII and when 
transcription elongation blockage occurs, additional p53 protein molecules are recruited while the occupancy of 
RNAPII is reduced. We assume that p53 plays a role in the removal of the stalled RNAPII from the chromatin.
Discussion
Here we report that p53 interacts with the transcriptionally competent forms of RNAPII and that p53 is present 
at transcriptionally active gene regions. Furthermore, we show that upon ActD-induced transcription blockage, 
the occupancy of RNAPII decreases, while p53 binding increases at regions of selected genes that harbour no 
canonical p53 sites. Our data suggest a novel role of p53, which might be required during transcription arrest.
Depending on its dosage, ActD can induce different molecular pathways. At a low concentration (5 nM), 
ActD mimics the effect of the Mdm2 inhibitor, nutlin-3, by abolishing RNAPI-mediated rRNA production. This 
leads to the accumulation of free ribosomal proteins, such as L11 and L23 that interact with and inhibit Mdm2. 
Figure 5. Human p53 binds to regions of genes which are not its direct targets. (A) ChIP-seq analysis of 
p53, RPB1, S2P RPB1 or S5P RPB1 occupancies results in the classification of 3 gene clusters. (B–E) p53 and 
RPB1 occupancies at the promoter, proximal (Gene body 1) and distal (Gene body 2) gene body and 3’UTR of 
ActB, Cdk12, Brat1, Sdcbp genes, respectively. On each graph, white columns represent untreated control, while 
grey and black columns indicate samples treated with 200 nM ActD for 6 and 24 h, respectively. The schematic 
structure for each gene and the location of the products amplified with qPCR are indicated. (F) For the positive 
control, p53 and RPB1 occupancies at the promoter of P21, a direct target gene of p53, are shown. (G) p53 and 
RPB1 occupancies at an intergenic region, which was used as a negative control. Each data point represents the 
average of measurements taken on two independent chromatin samples.
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Conversely, at a high concentration (200 nM), ActD induces DNA double-strand breaks leading to the inhibition 
of transcription elongation35. Indeed, it has been demonstrated that ActD treatment—similarly to UV irradia-
tion—can cause transcription elongation blockage by inhibiting the progression of the elongating RNAPII42,43.
During DNA double-strand break repair and UV-induced nucleotide excision repair, RNAPII becomes stalled 
at transcription units and these processes act as a so-called ‘last resort’ mechanism, finally activating the ubiqui-
tylation and degradation of RNAPII7,10,18. UV-induced transcription blockage leads to p53 activation and helps 
the recruitment of DNA repair proteins to the DNA lesions, which can ensure genome stability and reduce the 
chance of tumour formation8. p53 activation by phosphorylation at its Ser-15 residue was also described as an 
essential step during DNA double-strand break repair. We found that transcription elongation blockage activated 
the Ser-15 phosphorylation of p53.
We detected the co-localisation of p53 with the S5P and S2P forms of RPB1. Interestingly, 24 h after treatment 
with a high concentration of ActD, p53 co-localised with RPB1 to discrete nuclear foci, presumably at the sites 
of DNA damage. This observation is in agreement with a previous demonstration that in Caenorhabditis elegans, 
upon transcription inhibition, RNAPII is localised to discrete chromatin “degradation centres” and is degraded 
by the 26S proteasome21. Another explanation for the co-localisation of S5P RNAPII and p53 could be that at 
these sites, transcription has already been reinitiated following the successful repair after ActD-induced DNA 
damage. Finally, these sites could mark stress-responsive genes, which remain transcriptionally active following 
DNA damage44.
Re-analysis of existing ChIP-seq data revealed that p53 and RNAPII recruited to promoters (Cluster 1) and 
gene bodies (Cluster 2) of highly transcribed genes during the normal transcription cycle. High p53 enrichment 
detected by ChIP-seq data was also confirmed by the chromatin immunoprecipitation method on ActB, Cdk12, 
Brat1 and Sdcbp genes. Our data are in agreement with previous results29, which showed that in yeast, human 
p53 was bound to gene regions that do not contain any canonical p53 binding sites. At most of the examined 
regions of the four randomly chosen, non-direct p53 target genes, p53 occupancies increased after 6 and 24 h of 
transcription elongation blockage. On the other hand, RPB1 occupancy was reduced 6 h after ActD treatment 
and then restored after 24 h. ActB, however, behaved differently, since p53 and RPB1 occupancies showed similar 
distributions on this gene.
In this study, we showed that human p53 interacts with the largest subunit of RNAPII and that p53 co-traverses 
with the elongating RNAPII during transcription. If a transcription elongation blockage occurs, p53 and RPB1 
show different distributions in their chromatin association: the binding of the p53 protein to chromatin increases, 
while RPB1 occupancy decreases. These results suggest that in human cells, p53 can regulate transcription elon-
gation by a mechanism involving its interaction with RNAPII. Several studies have reported that the structural 
changes of the hyperphosphorylated S2P form of RPB1 promote its ubiquitin-mediated proteasomal degradation 
upon DNA damage19,45. In the case of UV-induced DNA damage, the hyperphosphorylation state of RPB1 does 
not allow a new PIC formation44,46. Furthermore, transcription blockage also induces the proteasomal degra-
dation of RPB118. Our results are in accordance with this phenomenon, as we report here that in human cells, 
upon induction of transcription elongation blockage, the degradation of the elongating form of RPB1 by the 26S 
proteasome might be influenced by p53.
Our data suggest that p53 may co-traverse with RNA polymerase II, similar to a transcription elongation 
factor, due to its interaction with RPB1. Our results indicate that RPB1 is degraded at the transcribed units by 
resolving the transcription blockage. This might serve to allow access for the repair proteins to the damaged DNA. 
The data we present in this paper provide a better understanding of how cells resolve transcription blockages 
when exposed to different stress conditions and the feedback mechanisms involved.
Methods
Cell lines, media and culture conditions. The U2OS cell line was cultured at 37 °C in DMEM (Dulbecco’s 
Modified Eagle Medium; Lonza) supplemented with 10% foetal calf serum (Lonza), 4 mM glutamine (Sigma-
Aldrich) and 1x antibiotic (Sigma-Aldrich).
Actinomycin D and MG132 treatment. Cells were treated with actinomycin D (ActD; Sigma-Aldrich) 
for 6 or 24 h. The cells were also treated with the proteasomal inhibitor, MG132 (Tocris Bioscience), 1 h before 
ActD treatment. ActD was used at concentrations of 5 nM or 200 nM and the final concentration of MG132 was 
20 μ M.
Micrococcal endonuclease (MNase) treatment. We treated cells with MNase (Thermo Fisher 
Scientific) in order to study whether the interaction between p53 and the transcriptionally active forms of RPB1 
was DNA-dependent. Before MNase treatment, 5 mM CaCl2 was added to each sample, which were then incu-
bated for 1 minute at 37 °C. MNase was added to the samples at a concentration of 0.066 U/μ l and they were incu-
bated for 10 minutes at 37 °C. The samples were then placed on ice in order to inactivate the enzyme.
ChIP-seq analysis. Published datasets were downloaded from The European Nucleotide Archive (http://
www.ebi.ac.uk/ena) under the following accession numbers: p53 and related input files (srr847010, srr847017); 
S2P RPB1 (srr987275); S5P RPB1 (srr987273); RPB1 (srr987271). All data were generated from the U2OS cell 
line.
The reference human genome (GRCh38/hg38 assembly) and annotated gene list were downloaded from the 
UCSC Genome Browser (www.ucsc.org). For the analysis described here, we have considered only the RefSeq 
genes that are reviewed and validated.
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ChIP-seq tag density values were extracted for every RefSeq gene over the annotated gene body and 
+ /− 1500 bp upstream and downstream from the loci, using the program seqMINER43,47. The average gene profile 
of ChIP-seq tags and differential binding patterns were identified using the methods described in Anamika et al.44,48.
Chromatin immunoprecipitation. Chromatin samples were prepared from U2OS cells. Cells were 
cross-linked with 1% formaldehyde (Sigma-Aldrich) for 10 minutes then incubated with 125 mM glycine 
(Sigma-Aldrich) for 5 minutes to stop fixation. Cells were collected using centrifugation for 5 minutes at 2000 rpm 
and 4 °C. Cell pellets were resuspended in a cell lysis buffer [5 mM PIPES (Sigma-Aldrich) pH 8.0, 85 mM KCl 
(Sigma-Aldrich), 0.5% NP-40 (IGEPAL; Sigma-Aldrich), 1x PIC-C (Protease Inhibitor Cocktail, Calbiochem)] 
and incubated on ice for 10 minutes. Cells were collected using centrifugation (2000 rpm, 5 minutes, 4 °C). Pellets 
were resuspended in a nuclear lysis buffer [50 mM Tris-HCl pH 8.0 (Sigma-Aldrich), 10 mM EDTA pH 8.0 
(Sigma-Aldrich), 0.8% SDS (Sigma-Aldrich), 1x PIC-C (Calbiochem)] and incubated on ice for 1 h. Chromatin 
samples were fragmented by sonication using Bioruptor (Diagenode). Chromatin samples were diluted four-fold 
with a dilution buffer [10 mM Tris-HCl pH 8.0 (Sigma-Aldrich), 0.5 mM EGTA pH 8.0 (Sigma-Aldrich), 1% 
Triton-X-100 (Sigma-Aldrich), 140 mM NaCl (Sigma-Aldrich), 1x PIC-C (Calbiochem)]. 30 μ g of pre-cleared 
chromatin was used for each immunoprecipitation. Immunoprecipitations were incubated overnight at 4 °C with 
the antibodies listed below, then chromatin-antibody complexes were collected with 40 μ l Sheep anti-Rabbit 
IgG Dynabeads (Novex) at 4 °C. After washing, chromatin-antibody complexes were eluted from beads, then 
DNA fragments were precipitated overnight at − 80 °C. After centrifugation, pellets were resuspended in TE 
(Tris-EDTA) buffer then reverse cross-linked at 50 °C for 2 h. DNAs were purified with phenol-chloroform 
extraction, then precipitated overnight with absolute ethanol at − 80 °C. The amount of extracted DNA was deter-
mined by Q-PCR using SYBR Green PCR Master Mix (Fermentas) in Thermo PikoReal 96 Real-Time PCR sys-
tem (Thermo Fisher Scientific). Sequences of primers used in the Q-PCR are listed in Supplementary Table S1.
Samples were quantified using a TIC (total input control) standard curve. The amount of DNA specifically 
precipitated by the given antibody was calculated by deducting the amount of DNA in the no-antibody control 
(NAC) from the total. The following antibodies were used in the ChIP experiments: hp53 ab17990 (Abcam), 
RPB1 (N-20) and sc-899 (Santa Cruz).
Co-immunoprecipitation. U2OS cells were lysed in a lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM 
Tris-HCl pH 8.0) containing 1x PIC-C (Calbiochem) and 1X PhosSTOP (Roche) on ice for an hour. After lysis, 
cell debris was pelleted by centrifugation at 2000 rpm, 4 °C for 5 minutes, then was discarded. 300 μ g lysates 
were pre-cleared for 2 h with blocked Protein A-Sepharose beads (Sigma-Aldrich). Polyclonal RNAPII antibody 
against S5P or S2P CTD (Abcam) was used for the immunoprecipitation. To control the co-immunoprecipitation, 
we used a p53 (Abcam) antibody for the reverse experiment. For detection of non-specific protein binding (IgG 
control) we added Protein A-Sepharose beads to the cell lysate, without a specific antibody. The protein-antibody 
complexes were collected with 40 μ l of blocked Protein A-Sepharose beads (Sigma-Aldrich). Then beads were 
washed for four times with lysis buffer supplemented with 1x PIC-C (Calbiochem). After washing, beads were 
boiled in 2x SDS loading buffer for 5 minutes and centrifuged at 13,000 rpm for 5 minutes at 4 °C. To detect the 
interaction between RPB1 and the p53 protein, monoclonal hp53 antibody (Dako) was used in 1:750 or 1:1500 
dilutions and polyclonal S15P p53 antibody (Cell signalling) was used in 1:250 or 1:500 dilutions in the immuno-
precipitated and input samples, respectively. For reverse immunoprecipitation, the antibody against S5P CTD of 
RPB1 (Abcam) was used in 1:1000 or 1:2000 dilutions, and the antibody against S2P CTD of RPB1 (Abcam) was 
used in 1:500 or 1:1000 dilutions, in the immunoprecipitated and input samples, respectively. For p53 detection, 
we used the anti-kappa light chain secondary antibody (from L. Tora, IGBMC).
Immunocytochemistry. U2OS cells were washed with PBS (Phosphate-buffered saline), then rinsed 
twice for 3 minutes with CSK (Cytoskeletal) buffer [10 mM HEPES pH 7.0 (Sigma-Aldrich), 100 mM NaCl 
(Sigma-Aldrich), 300 mM sucrose (Molar Chemicals), 3 mM MgCl2 (Molar Chemicals), 0.7% Triton-X-100 
(Fluka) and 0.3 mg/ml RNase A (Sigma-Aldrich)]. Cells were rinsed twice with PBS, then fixed with 4% formal-
dehyde (Sigma-Aldrich) for 10 minutes. After washing, cells were permeabilised for 5 minutes in PBS containing 
0.2% Triton-X-100 (Fluka). Non-specific staining was blocked with 5% BSA in PBST [0.1% Tween 20 (Molar 
Chemicals) in PBS] for 20 minutes. Cells were incubated with the following primary antibodies: anti-p53 (Dako, 
IS616), N-20 anti-RPB1 (Santa Cruz, sc899), anti-S2P RPB1 (Abcam, ab5095), anti-S5P RPB1 (Abcam, ab5131), 
anti-S139P H2AX (Millipore, 05-636-I) and anti-S139P H2AX (ab2893). After washing, the following secondary 
antibodies were used: GAM Alexa 488 (Molecular Probes, A11029) and GAR DyLight 550 (Abcam, ab96984). 
Both the primary and secondary antibodies were applied in 1% BSA-PBST. Coverslips were mounted on glass 
slides using DAPI containing ProLong Gold Antifade reagent (Life Technologies). Samples were visualised with 
Olympus FluoView FV1000 confocal microscope. The same exposition time was used to capture each image.
Western blot. U2OS cells were harvested in lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris-HCl 
pH 8.0; Sigma-Aldrich) supplemented with 1x PIC-C (Calbiochem), incubated on ice for an hour, then centri-
fuged (13,000 rpm at 4 °C for 5 minutes). The supernatant lysates were mixed with the same amount of 2x SDS 
loading buffer containing 5% β -mercaptoethanol (Sigma-Aldrich) and boiled for 5 minutes. The lysates were sep-
arated in SDS-PAGE, transferred to Amersham Hybond ECL-membrane (GE Healthcare) and incubated with the 
following primary antibodies: anti-p53 (Dako, IS616), anti-S15 P p53 (Cell signalling, 9284), 1BP7G5 anti-RPB1 
(from L. Tora, IGBMC), anti-S2P RPB1 (Abcam, ab5095) and anti-S5P RPB1 (Abcam, ab5131), anti-GAPDH 
(Millipore, MAB374); then the following secondary antibodies: RAM-HRP (Dako, P0260) and GAR-HRP (Dako, 
P0448). Chemiluminescent detection was conducted using Immobilon Western Chemiluminescent HRP sub-
strate (Millipore).
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